This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
About
Associate Professor Lauren Ayton
Principal Research Fellow, Retinal Gene Therapy Unit and VENTURE Study
Associate Professor Lauren Ayton is a Principal Research Fellow at CERA, with research interests in inherited retinal disease and gene therapy.
Associate Professor Lauren Ayton
Principal Research Fellow, Retinal Gene Therapy Unit and VENTURE Study
BOptom, PhD, FAAO, FACO, GAICD
Associate Professor Lauren Ayton is a member of CERA’s Executive team and co-leads the Retinal Gene Therapy Unit and VENTURE inherited retinal diseases (IRD) registry with Dr Tom Edwards.
She is also the Head of the Vision Optimisation Unit at the University of Melbourne.
Her research interests are IRD, low vision, and interventions to assist people with IRD, including gene therapy.
Associate Professor Ayton has previously held senior roles in bionic eye projects in both Australia (at CERA) and in the USA (Harvard/Cornell Universities). She has experience working in industry, as a Director of Clinical and Regulatory Affairs, and is currently the interim Associate Dean of Innovation and Enterprise for the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne.
Associate Professor Ayton and Dr Edwards’ team are working to provide people with IRDs opportunities to be involved in research at all stages, from natural history studies, online surveys and questionnaires, or clinical treatment trials.
She is an investigator at Cerulea Clinical Trials and has been involved in 11 industry IRD clinical trials to date.
Current projects
Key publications
Key collaborators
Funding and support
Current projects
- VENTURE Inherited Retinal Disease Natural History Registry
- Female carriers of X-linked inherited retinal disease.
- Sensory substitution devices for people with low vision, to assist with mobility and activities of daily living.
- Nacuity clinical trial of a neuroprotection therapy for patients with Usher Syndrome.
- Gyroscope gene therapy clinical trial for age-related macular degeneration associated with geographic atrophy (dry AMD).
- Belite oral medication clinical trial for adolescents with Stargardt disease.
- Janssen Chromeos natural history study for achromatopsia.
Key publications
, , , , the VENTURE Study Consortium. Victorian evolution of inherited retinal diseases natural history registry (VENTURE study): Rationale, methodology and initial participant characteristics. Clin Experiment Ophthalmol. 2022; 1– 13. doi:10.1111/ceo.14110
Lauren N. Ayton, Joseph F. Rizzo, Ian L. Bailey, August Colenbrander, Gislin Dagnelie, Duane R. Geruschat, Philip C. Hessburg, Chris D. McCarthy, Matthew A. Petoe, Gary S. Rubin, Philip R. Troyk, for the HOVER International Taskforce; Harmonization of Outcomes and Vision Endpoints in Vision Restoration Trials: Recommendations from the International HOVER Taskforce. Trans. Vis. Sci. Tech. 2020;9(8):25. doi: https://doi.org/10.1167/tvst.9.8.25.
Ayton LN, Blamey PJ, Guymer RH, Luu CD, Nayagam DAX, et al. (2014) First-in-Human Trial of a Novel Suprachoroidal Retinal Prosthesis. PLOS ONE 9(12): e115239.https://doi.org/10.1371/journal.pone.0115239
More publications:
https://findanexpert.unimelb.edu.au/profile/122819-lauren-ayton
https://scholar.google.com.au/citations?user=XxGGFKMAAAAJ&hl=en
Key collaborators
Funding and support
Thank you to the following for their support:
- NHMRC Investigator Grant
- Retina Australia
- University of Melbourne
Contact Associate Professor Lauren Ayton
Leave a direct enquiry for CERA below!
Please note: Unfortunately we are not able to provide individual medical advice over email.
